Daily Endocrinology Research Analysis
Three high-impact studies shape current endocrinology-adjacent practice: a Nature Communications analysis clarifies dairy-CVD associations across biobanks and meta-analysis; a large EHR-based EClinicalMedicine study finds no increased 12-month neuropsychiatric risk with semaglutide vs comparators; and a JCEM cohort shows adiponectin and leptin differentially predict transitions in metabolic health. Together, they inform dietary guidance, GLP-1RA safety counseling, and risk stratification.
Summary
Three high-impact studies shape current endocrinology-adjacent practice: a Nature Communications analysis clarifies dairy-CVD associations across biobanks and meta-analysis; a large EHR-based EClinicalMedicine study finds no increased 12-month neuropsychiatric risk with semaglutide vs comparators; and a JCEM cohort shows adiponectin and leptin differentially predict transitions in metabolic health. Together, they inform dietary guidance, GLP-1RA safety counseling, and risk stratification.
Research Themes
- Dietary patterns and cardiometabolic risk across populations
- GLP-1 receptor agonists: neuropsychiatric safety over 12 months
- Adipokines as predictors of metabolic health transitions
Selected Articles
1. A global analysis of dairy consumption and incident cardiovascular disease.
Leveraging two large biobanks and an updated meta-analysis, this study finds heterogeneous associations of dairy with CVD across populations: in China (mainly whole milk) higher CHD and lower stroke risk; in the UK, lower risks for CVD, CHD, and ischemic stroke with notable protective associations for cheese and low-fat milk. The pooled meta-analysis supports modest risk reductions for total CVD and stroke.
Impact: Clarifies a long-standing controversy by integrating multi-country cohort data with meta-analysis, distinguishing effects by dairy subtype and fat content. Findings can inform nuanced dietary guidance rather than one-size-fits-all recommendations.
Clinical Implications: Dietary counseling can emphasize cheese and low-fat dairy as potentially cardioprotective, while cautioning that whole milk patterns may differ by population context. Guidance should be tailored to local dietary patterns and overall cardiometabolic risk.
Key Findings
- In China, regular dairy (mainly whole milk) was associated with a 9% higher CHD risk and a 6% lower stroke risk versus non-consumers.
- In the UK, total dairy intake was linked to lower risks of CVD, CHD, and ischemic stroke; cheese and semi-skimmed/skimmed milk contributed to reduced CVD risk.
- Meta-analysis showed total dairy associated with 3.7% lower CVD and 6% lower stroke risk.
- Inverse associations were strongest for cheese and low-fat dairy products.
Methodological Strengths
- Integration of two large biobanks with an updated meta-analysis enhances generalizability.
- Product-specific (cheese, low-fat milk) analyses enable mechanistically plausible interpretation.
Limitations
- Observational design susceptible to residual confounding and reverse causation.
- Dietary assessment and dairy subtype classification may be imprecise; cultural dietary differences complicate comparisons.
Future Directions: Randomized or quasi-experimental substitution trials comparing dairy subtypes; mechanistic studies on fermentation, calcium, and saturated fat matrices; region-specific dietary modeling for guideline development.
The role of dairy products in cardiovascular disease (CVD) prevention remains controversial. This study investigates the association between dairy consumption and CVD incidence using data from the China Kadoorie Biobank and the UK Biobank, complemented by an updated meta-analysis. Among Chinese participants, regular dairy consumption (primarily whole milk) is associated with a 9% increased risk of coronary heart disease (CHD) and a 6% reduced risk of stroke compared to non-consumers. Among British participants, total dairy consumption is linked to lower risks of CVD, CHD, and ischemic stroke, with cheese and semi-skimmed/skimmed milk contributing to reduced CVD risk. Meta-analysis reveals that total dairy consumption is associated with a 3.7% reduced risk of CVD and a 6% reduced risk of stroke. Notably, inverse associations with CVD incidence are observed for cheese and low-fat dairy products. Current evidence suggests that dairy consumption, particularly cheese, may have protective effects against CVD and stroke.
2. Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study.
In 8,423 ARIC participants over 6 years, each 1-SD higher adiponectin predicted lower odds of progressing from metabolically healthy to unhealthy and higher odds of regressing to healthy, while leptin showed the opposite pattern. These associations persisted across obesity strata; leptin associations attenuated after BMI adjustment, whereas adiponectin’s remained robust.
Impact: Identifies differential roles of adipokines in metabolic health transitions, offering mechanistic epidemiology for risk stratification and potential therapeutic targeting.
Clinical Implications: Adiponectin and leptin can refine risk prediction for metabolic deterioration and improvement, aiding personalized prevention strategies in obesity care.
Key Findings
- Per 1-SD higher adiponectin: lower odds of progression from healthy to unhealthy (OR 0.53) and higher odds of regression to healthy (OR 1.58).
- Higher leptin: higher odds of progression (OR 2.22) and lower odds of regression (OR 0.68).
- Associations were consistent across obesity strata; leptin associations attenuated after BMI adjustment, adiponectin’s remained similar.
Methodological Strengths
- Prospective design with clearly defined 6-year transitions in metabolic health.
- Stratified analyses by obesity and adjustment for BMI enhance interpretability.
Limitations
- Observational study cannot establish causality; residual confounding possible.
- Single-time adipokine measurements may not capture temporal variability.
Future Directions: Interventional studies to modulate adipokines; Mendelian randomization to probe causality; integration with omics to identify pathways driving transitions.
CONTEXT: Transitions in metabolic health status over time are strongly linked to risk for cardiovascular events, particularly among individuals with obesity. Adipokines are proteins with metabolic effects, but their role in transitions in metabolic health status over time is unknown. OBJECTIVE: To evaluate the associations of adiponectin and leptin with metabolic risk transitions over time. METHODS: Among 8423 individuals who attended ARIC Visits 2 (1990-1992) and 4 (1996-1998), we evaluated prospective associations of Visit 2 levels of the adipokines adiponectin and leptin (per 1-SD higher) with 6-year transitions in metabolic health. Metabolic health was categorized as metabolically "healthy" [no metabolic syndrome (MetS) or diabetes], unhealthy (MetS present) without diabetes, or unhealthy with diabetes. Analyses were performed overall and stratified by obesity [body mass index (BMI) ≥ 30 kg/m2]. RESULTS: At Visit 2, the mean age was 58, with 56% female and 21% Black adults. Adults with 1-SD higher adiponectin were less likely to progress from metabolically healthy to unhealthy status over 6 years [odds ratio (OR) 0.53, 95% confidence interval (CI): 0.48-0.57], while those with higher leptin were more likely to progress (OR 2.22, 95% CI: 2.01-2.47). Conversely, those with 1-SD higher adiponectin were more likely to regress from metabolically unhealthy to healthy status (OR 1.58, 95% CI: 1.42-1.76), while those with higher leptin were less likely to regress (OR 0.68, 95% CI: 0.60-0.78). Similar patterns were seen across obesity strata. After adjustment for BMI, associations of adiponectin with metabolic transitions were similar, whereas associations for leptin were significantly attenuated. CONCLUSION: Leptin and adiponectin are differentially linked to the likelihood of worsening and improving metabolic health over time. Adipokines should be explored as targets to improve metabolic health and decrease the risk of future cardiovascular events.
3. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
In propensity-matched cohorts from a US EHR network, semaglutide was not associated with higher 12-month risks across 22 neurological and psychiatric outcomes versus sitagliptin, empagliflozin, or glipizide. Signals of potential benefit for cognitive deficit and nicotine misuse merit prospective validation.
Impact: Addresses widely discussed safety concerns around GLP-1RAs with large-scale real-world data and robust matching, informing clinicians and regulators.
Clinical Implications: Supports reassurance when counseling T2D patients about neuropsychiatric risks with semaglutide; encourages targeted monitoring and prioritization of RCTs for cognitive outcomes.
Key Findings
- Semaglutide showed no increased 12-month risk across 22 neurological/psychiatric outcomes versus sitagliptin, empagliflozin, or glipizide after 1:1 propensity matching.
- Potential beneficial associations observed for cognitive deficit and nicotine misuse.
- Negative control outcomes were used to probe residual confounding.
Methodological Strengths
- Large, multi-institution EHR with propensity-score matching across three active comparators.
- Use of negative control outcomes to assess unmeasured confounding.
Limitations
- Retrospective, non-registered analysis; potential misclassification and residual confounding remain.
- Some outcomes may be underpowered or variably captured in EHR data.
Future Directions: Prospective randomized trials focused on cognitive and addiction-related outcomes; mechanistic studies on GLP-1R signaling in brain circuits.
BACKGROUND: While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of semaglutide on brain health. This study provides robust estimates of the risk of neurological and psychiatric outcomes following semaglutide use compared to three other antidiabetic medications. METHODS: This retrospective cohort study used electronic health records from TriNetX US Collaborative Network, covering >100 million patients in the USA. Due to the exploratory nature of this study, we did not use a pre-registered protocol or statistical analysis plan. Three cohorts with T2DM prescribed semaglutide between 1st December 2017 and 31st May 2021 were propensity-score matched (1:1 using a greedy nearest-neighbour algorithm with calliper distance of 0.1) with cohorts receiving sitagliptin, empagliflozin, and glipizide. Using Cox regression analysis, we compared the risks of 22 neurological and psychiatric outcomes within one year since the index prescription: encephalitis, parkinsonism, cognitive deficit, dementia, epilepsy/seizure, migraine, insomnia, nerve disorder, myoneural junction/muscle disease, intracranial haemorrhage, ischaemic stroke, alcohol misuse, opioid misuse, cannabis misuse, stimulants misuse, nicotine misuse, psychosis, bipolar disorder, depression, anxiety, obsessive-compulsive disorder, and suicidality. Negative control outcomes (NCOs) were used to assess unmeasured confounding. FINDINGS: Each matched cohort included 23,386 (semaglutide INTERPRETATION: Semaglutide is not associated with higher 12-month risk of adverse neuropsychiatric outcomes compared to other antidiabetic medications. Potential beneficial associations with some outcomes, especially cognitive deficit and nicotine misuse, should stimulate validation in clinical trials. FUNDING: National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre, Medical Research Council.